Literature DB >> 26949612

Management strategies in malignant glaucoma secondary to antiglaucoma surgery.

Zuo-Hong Wu1, Yu-Hong Wang1, Ying Liu2.   

Abstract

AIM: To assess the outcomes of various interventions for malignant glaucoma (MG).
METHODS: A retrospective, comparative analysis of case series were performed on 38 eyes of 35 MG patients treated in Aier Eye Hospital of Wuhan between Jan. 2009 and Dec. 2012. Numerous treatments were administered including medical therapy, neodymium: yttrium- aluminium-garnet (Nd:YAG) laser posterior capsulotomy and hyaloidotomy as well as 3 surgical options. The characteristic, treatment option and outcome of MG in every individual patient were reviewed and analyzed among all patients who were followed up for an average of 27.1±9.1mo.
RESULTS: Four eyes of 3 patients achieved complete resolution with medical therapy. Nd:YAG laser posterior capsulotomy and hyaloidotomy were performed on 2 eyes, both of which achieved resolution after initial intervention. Thirty-two eyes were given surgical treatments with anterior vitrectomy- reformation of anterior chamber in 13 eyes, phacoemulsification- intraocular lens implantation in 10 eyes and phacoemulsification- intraocular lens implantation- anterior vitrectomy in 9 eyes. Resolution of MG was seen in almost all patients. The mean intraocular pressure decreased from 41.87±9.44 mm Hg at presentation to 15.84±3.73 mm Hg at the last visit. The mean anterior chamber depth improved from 0.28±0.27 mm to 2.28±0.19 mm. Twenty eyes with preoperative visual acuity better than counting figure/ 50 cm had various visual improvements. Complications occurred in 3 eyes of 3 patients including bleeding at the entry site of vitrectomy into vitreous cavity, corneal endothelial decompensation and allergic to atropine respectively.
CONCLUSION: MG occurs as a result of multiple mechanisms involved simultaneously or sequentially.Medical therapy is advocated as the initial treatment, laser therapy is beneficial in pseudophakic eyes, and different surgical regimen is recommended based on different pathogenesis of MG when non-response occurs to nonsurgical management. MG can be managed successfully by appropriate and timely interventions with good visual outcome.

Entities:  

Keywords:  laser therapy; malignant glaucoma; medical therapy; pathogenesis; surgical interventions

Year:  2016        PMID: 26949612      PMCID: PMC4768516          DOI: 10.18240/ijo.2016.01.11

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  17 in total

Review 1.  Possible mechanisms of primary angle-closure and malignant glaucoma.

Authors:  Harry A Quigley; David S Friedman; Nathan G Congdon
Journal:  J Glaucoma       Date:  2003-04       Impact factor: 2.503

2.  Surgical management of malignant glaucoma with white cataract in nanophthalmos.

Authors:  Yi-fan Feng; Dan-dan Wang; Yun-e Zhao; Jun-hua Li; Giacomo Savini; Jin-hai Huang
Journal:  J Cataract Refract Surg       Date:  2013-09-07       Impact factor: 3.351

3.  25-Gauge pars plana vitrectomy for ciliary block (malignant) glaucoma.

Authors:  Li Meng; Wenbin Wei; Yanlong Li; Xiaoying Hui; Xiaodong Han; Xiaobo Shi
Journal:  Int Ophthalmol       Date:  2014-07-26       Impact factor: 2.031

Review 4.  Malignant glaucoma and its management.

Authors:  S Ruben; J Tsai; R A Hitchings
Journal:  Br J Ophthalmol       Date:  1997-02       Impact factor: 4.638

5.  Phacoemulsification combined with posterior capsulorhexis and anterior vitrectomy in the management of malignant glaucoma in phakic eyes.

Authors:  Xing Liu; Mei Li; Bing Cheng; Zhen Mao; Yimin Zhong; Dandan Wang; Dan Cao; Fenfen Yu; Nathan G Congdon
Journal:  Acta Ophthalmol       Date:  2012-06-07       Impact factor: 3.761

6.  Vitrectomy-phacoemulsification-vitrectomy for the management of aqueous misdirection syndromes in phakic eyes.

Authors:  Ash Sharma; Freda Sii; Peter Shah; Graham R Kirkby
Journal:  Ophthalmology       Date:  2006-11       Impact factor: 12.079

7.  [Diode laser in "Malignant Glaucoma" treatment].

Authors:  H Bresson Dumont; L Ballereau; A Lehoux; P-Y Santiago
Journal:  J Fr Ophtalmol       Date:  2006-05       Impact factor: 0.818

8.  Transscleral cyclodiode laser photocoagulation in the treatment of aqueous misdirection syndrome.

Authors:  Thomas H Stumpf; Michael Austin; Philip A Bloom; Andrew McNaught; James E Morgan
Journal:  Ophthalmology       Date:  2008-07-31       Impact factor: 12.079

9.  Treatment outcomes in malignant glaucoma.

Authors:  Paaraj Dave; Sirisha Senthil; Harsha L Rao; Chandra S Garudadri
Journal:  Ophthalmology       Date:  2013-01-31       Impact factor: 12.079

10.  Angle-closure glaucoma-simpler answers to complex mechanisms: LXVI Edward Jackson Memorial Lecture.

Authors:  Harry A Quigley
Journal:  Am J Ophthalmol       Date:  2009-11       Impact factor: 5.258

View more
  5 in total

1.  Comment on "Management strategies in malignant glaucoma secondary to antiglaucoma surgery".

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

2.  Application of Nd:YAG laser to the anterior vitreous in malignant glaucoma - a systemic review and meta-analysis.

Authors:  Margarita Safir; Idan Hecht; Tal Sharon; Adi Einan-Lifshitz; Avner Belkin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-29       Impact factor: 3.535

3.  Vitreociliary Block in a Patient With Uveitis and Previous Laser Posterior Capsulotomy.

Authors:  Ana-María Dorado-López-Rosado; Enrique Mencía-Gutiérrez; María Polo-García; Esperanza Gutiérrez-Díaz
Journal:  Cureus       Date:  2021-05-01

4.  Clinical Efficacy of Ciliary Ring Incision Combined with Modified Partial Pars Plana Vitrectomy for Malignant Glaucoma.

Authors:  Jianchun Yu; Xing Chen; Danying Zhou; Jian Shen; Yanbing Wu; Qingzhu Sun
Journal:  Med Sci Monit       Date:  2018-06-10

Review 5.  Acute and chronic fluid misdirection syndrome: pathophysiology and treatment.

Authors:  Andrzej Grzybowski; Piotr Kanclerz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-06       Impact factor: 3.535

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.